In vivo and in vitro protective effects of shengmai injection against doxorubicin-induced cardiotoxicity.

ABSTRACT:

Context

Shengmai injection (SMI) has been used to treat heart failure.

Objective

This study determines the molecular mechanisms of SMI against cardiotoxicity caused by doxorubicin (DOX).

Materials and methods

In vivo, DOX (15 mg/kg) was intraperitoneally injected in model, Dex (dexrazoxane), SMI-L (2.7 mL/kg), SMI-M (5.4 mL/kg), and SMI-H (10.8 mL/kg) for 7 consecutive days. Hematoxylin-eosin (HE) and Masson staining were used to evaluate histological changes, and cardiomyocyte apoptosis was identified using TdT-mediated dUTP nick-end labelling (TUNEL). Enzymatic indexes were determined. mRNA and protein expressions were analysed through RT-qPCR and Western blotting. In vitro, H9c2 cells were divided into control group, model group (2 mL 1 μM DOX), SMI g

SUBMITTER: Zhou P 

PROVIDER: S-EPMC8933025 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature